Core Insights - Medtronic reported strong second-quarter 2026 results with sales of $8.96 billion, exceeding the consensus estimate of $8.87 billion, representing a 6.6% year-over-year increase and 5.5% organic growth [1] - Adjusted earnings per share were $1.36, surpassing expectations of $1.31, indicating robust procedure volumes and effective execution across the business [1] - The company raised its fiscal year 2026 organic revenue growth guidance to 5.5% from 5% and adjusted earnings guidance to $5.62-$5.66 per share, compared to the previous $5.60-$5.66 [2] Financial Performance - Sales reached $8.96 billion, a 6.6% increase year-over-year with organic growth of 5.5% [1] - Adjusted earnings per share of $1.36 exceeded expectations of $1.31 [1] - Fiscal year 2026 guidance includes a potential tariff impact of approximately $185 million, unchanged from prior guidance, with diluted adjusted earnings per share growth of approximately 4.5% when excluding tariffs [2] Analyst Ratings and Price Targets - Goldman Sachs upgraded Medtronic from Sell to Neutral, raising the price target from $81 to $111 [5] - Baird maintained a Neutral rating and increased the price target from $103 to $109 [5] - Wells Fargo maintained an Overweight rating, raising the price target from $100 to $114 [5] - UBS maintained a Neutral rating and raised the price target from $95 to $102 [5] - RBC Capital maintained an Outperform rating, increasing the price target from $111 to $118 [5] - Morgan Stanley maintained an Overweight rating, raising the price target from $107 to $117 [5]

Core Insights - Coca-Cola reported a 5% revenue growth in Q3 2025, reaching $12.455 billion, exceeding market expectations of $12.41 billion [1] - Organic revenue increased by 6%, with net profit rising by 29% to $3.683 billion [1] - Earnings per share (non-GAAP) grew by 6% to $0.82, surpassing the market forecast of $0.78 [1] Revenue Drivers - The revenue growth was primarily driven by average price increases and product mix optimization, with a price increase of approximately 6% in Q3 [1][2] - The Asia-Pacific market, including China, saw a 13% year-over-year increase in operating profit, supported by favorable pricing strategies and product mix, with a price/product mix growth of 8% [1][4] Market Performance - Global unit case volume increased by 1% in Q3, with flagship Coca-Cola brand volume growing by 1%, mainly driven by Europe, the Middle East, Africa, and Asia-Pacific markets [2] - Notably, the sales of no-sugar Coca-Cola surged by 14%, while other product categories like juices and dairy saw declines [2][3] Strategic Investments - Coca-Cola reaffirmed its commitment to the Chinese market, with significant investments in new production facilities [1][4] - Two new factories in Shaanxi and Henan were completed and put into operation, alongside the completion of the main structure of the Greater Bay Area smart green production base [4][5][7] Future Outlook - The company reiterated its 2025 performance guidance, expecting a comparable currency-neutral earnings per share growth of approximately 8%, up from a previous estimate of 7%-9% [3] - The forecast for organic revenue growth for the full year 2025 remains at 5% to 6%, consistent with prior expectations [3]